NuCana (NCNA) Cash from Financing Activities (2017 - 2025)
NuCana (NCNA) reported Cash from Financing Activities of $9311.2 for Q4 2025, down 99.67% on a YoY basis from $2.8 million in Q4 2024, and down 99.95% sequentially from $20.6 million in Q3 2025.
NuCana (NCNA) Cash from Financing Activities (2017 - 2025) Analysis & Trends
NuCana (NCNA) has 9 years of Cash from Financing Activities data on file, last reported at $9311.2 in Q4 2025.
- For the quarter ending Q4 2025, Cash from Financing Activities fell 99.67% year-over-year to $9311.2; the trailing twelve-month figure through Dec 2025 stood at $29.5 million (up 178.93% YoY), and the FY2025 full-year result was $33.0 million, up 215.16% from the prior year.
- Cash from Financing Activities eased to $9311.2 in Q4 2025, from $20.6 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $20.6 million in Q3 2025 to a low of -$103431.9 in Q2 2021.
- A 5-year average of $1.7 million and a median of -$44807.7 in 2022 frame the typical range for Cash from Financing Activities.
- Across the five-year window, Cash from Financing Activities sank 268.52% in 2023 and soared 7394.38% in 2024, its largest moves.
- Tracing NCNA's Cash from Financing Activities over 5 years: stood at -$99752.8 in 2021, then soared by 131.75% to $31669.1 in 2022, then plunged by 268.52% to -$53369.5 in 2023, then jumped by 5354.78% to $2.8 million in 2024, then slumped by 99.67% to $9311.2 in 2025.
- Business Quant data shows NCNA's Cash from Financing Activities at $9311.2 in Q4 2025, $20.6 million in Q3 2025, and $2.8 million in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 68.63 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 9,311.16 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 238.74 Mn |
| 10 | Alnylam Pharmaceuticals | 35.71 Bn | 32.70 Bn | 959.66 Mn | 15.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 9,311.16 |
| Dec 31, 2025 | 9,311.16 |
| Sep 30, 2025 | 20.56 Mn |
| Sep 30, 2025 | 20.56 Mn |
| Dec 31, 2024 | 2.80 Mn |
| Dec 31, 2024 | 2.80 Mn |
| Sep 30, 2024 | 6.08 Mn |
| Sep 30, 2024 | 6.08 Mn |
| Jun 30, 2024 | -79,519.91 |
| Jun 30, 2024 | -79,519.91 |
| Mar 31, 2024 | 1.76 Mn |
| Mar 31, 2024 | 1.76 Mn |
| Dec 31, 2023 | -53,369.53 |
| Dec 31, 2023 | -53,369.53 |
| Sep 30, 2023 | 81,067.83 |
| Sep 30, 2023 | 81,067.83 |
| Jun 30, 2023 | -41,294.98 |
| Jun 30, 2023 | -41,294.98 |
| Mar 31, 2023 | -49,835.89 |
| Mar 31, 2023 | -49,835.89 |